Navigation Links
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
Date:10/25/2007

Submission Seeks Approval of Genasense in Relapsed/Refractory Patients

BERKELEY HEIGHTS, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Company has completed the filing of the Company's formal appeal to Dr. Janet Woodcock, Acting Director of the Center for Drug Evaluation Research (CDER), at the U.S. Food and Drug Administration (FDA). The appeal asks that CDER approve the use of Genasense(R) (oblimersen sodium) Injection plus chemotherapy for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In December 2006, FDA issued a non-approvable letter for the Company's New Drug Application (NDA) for Genasense in CLL. This appeal has been submitted in accordance with the Formal Dispute Resolution process that exists within CDER. Responses to CDER appeals are typically made within 30 to 60 days.

The appeal reflects several considerations, including but not limited to the following:

- Complete responses -- the primary endpoint of the trial - were more

than doubled in the Genasense group compared with controls who received

chemotherapy alone. The difference was statistically significant.

- Complete response confers clinical benefit in CLL. By definition, a

complete response requires elimination of all evidence of disease,

normalization of blood counts, and resolution of symptoms.

- The median duration of complete response in patients who received

Genasense has exceeded 3 years, at least 50% longer compared with

controls, which is clinically meaningful and statistically significant.

Survival information from this study will be updated at the annual

meeting of the Ameri
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- BioClinica®, Inc., a leading provider of outsourced clinical ... its experts are speaking at the 20th Annual ... held September 28 to October 1 in ... the innovative Compass technology, a risk-based monitoring ... earlier this year, is up for the Technology ...
(Date:9/17/2014)... Alternative Fuels Americas, Inc. (AFAI) announced today that ... Vehicle in partnership with Jatro Greentech, Inc., a ... SPV shall be called AFAI Jatro Green Ethiopia and will ... The SPV shall pursue Jatropha planting and biofuels production projects ... . "Although we have experienced great ...
(Date:9/17/2014)... Beckman Coulter , a global ... has renewed its agreement with Personify for ... agreement, Personify will continue to streamline the Beckman Coulter ... analytics, including time-to-fill, time-to-source and a deep reduction to ... Personify was based on the success of our partnership ...
(Date:9/17/2014)... 2014 The Alliance for ... multi-stakeholder non-profit collaborative building a global system to ... today announced Phase 3 of its Site Accreditation ... Amir H. Kalali, Vice-President, Global Head, Neuroscience Center ... Compliance and Quality Integration (CQI) Consulting will lead ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4
... N.J., Aug. 13 Soligenix, Inc. (OTC Bulletin ... press release contains forward-looking statements that reflect Soligenix, ... prospects and opportunities. Statements that are not historical ... expressions, are forward-looking statements. These statements are subject ...
... have fashioned nanowires into a new type of V-shaped transistor ... interior of cells. The new device, described this week ... viruses and about one-hundredth the width of the probes now ... large as the cells themselves. Its slenderness is a marked ...
... of Calgary, Faculty of Medicine scientists who proved it is ... on a silicon chip or the brain on a ... technology that monitors brain cell activity at a resolution never ... Canada (NRC), the new silicon chips are also simpler to ...
Cached Biology Technology:Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments 2New nanoscale transistors allow sensitive probing inside cells 2Neurochip technology developed by Canadian team 2
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
(Date:9/16/2014)... (September 17, 2014)The North American Menopause Society (NAMS) ... comprehensive care of midlife womenon everything from hot ... North American Menopause Society Recommendations for Clinical Care ... the Society,s journal Menopause . This is ... the care of midlife women freely available to ...
(Date:9/16/2014)... same viruses that make us sick can take up ... a sneeze, cough or other troublesome symptom, according to ... St. Louis. , On average, healthy individuals carry ... researchers report online in BioMed Central Biology . ... the diversity of viruses in healthy people. , ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3
... was identified by ancient Egyptians. Genetic analysis done by ... the animal,s range and including DNA from mummified crocodile remains ... name., "This paper provides a remarkable surprise: the Nile crocodile ... demonstrates two species - living side-by side - constitute what ...
... Bone marrow-derived stem cells (BMDCs) have been recognized as ... cell populations in a variety of organs under both normal ... repairing damaged brain tissue or helping to restore lost neural ... cerebellum at the back of the brain. In a recent ...
... Webb from the School of Chemical Engineering and Analytical ... and Excellence Award for Bioprocessing. They received the ... co-production of fuels and chemicals: The biochemical production of ... place last month at the ICC in Birmingham. ...
Cached Biology News:Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2Award success for University 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: